Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) Altman Z-Score: 3.85 (As of Jul. 06, 2026) — 26% Above Median


CAI:RMDA Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents CAI:RMDA
84 GF Score
Price E£5.10
GF Value E£4.08
Valuation Modestly Overvalued
! 9 Warning Signs
View Full Analysis

What is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Altman Z-Score?

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents CAI:RMDA +1.80% 84 Altman Z-Score is 3.85 as of Jul. 06, 2026, which is 26% above its 10-year median of 3.06. GuruFocus rates CAI:RMDA with a GF Score™ of 84/100 and a GF Value™ of E£4.08 (Modestly Overvalued). The stock has 9 warning signs investors should review. Among 952 Drug Manufacturers companies, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents ranks better than 55.04% on this metric.

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Good Sign:

Altman Z-score of 3.81 is strong.

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents has a Altman Z-Score of 3.85, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Altman Z-Score or its related term are showing as below:

CAI:RMDA' s Altman Z-Score Range Over the Past 10 Years
Min: 2.44   Med: 3.06   Max: 4.18
Current: 3.81

During the past 8 years, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's highest Altman Z-Score was 4.18. The lowest was 2.44. And the median was 3.06.


Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents  (CAI:RMDA) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Altman Z-Score Related Terms


Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Altman Z-Score Historical Data

* Premium members only.

The historical data trend for Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Altman Z-Score Chart

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Altman Z-Score
Get a 7-Day Free Trial 2.86 3.07 2.78 3.28 3.04

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.63 3.28 3.13 3.04 3.44

CAI:RMDA vs ZTS, UTHR, VTRS: Altman Z-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Altman Z-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Altman Z-Score falls into.


CAI:RMDA
84GF Score
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents CAI:RMDA
Altman Z-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.0952+1.4*0.222+3.3*0.1846+0.6*3.3401+1.0*0.8098
=3.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2026:
Total Assets was E£5,306 Mil.
Total Current Assets was E£3,409 Mil.
Total Current Liabilities was E£2,904 Mil.
Retained Earnings was E£1,178 Mil.
Pre-Tax Income was 136.74 + 58.536 + 127.606 + 126.155 = E£449 Mil.
Interest Expense was -130.036 + -130.512 + -137.057 + -132.944 = E£-531 Mil.
Revenue was 1066.778 + 1132.311 + 1134.754 + 963.332 = E£4,297 Mil.
Market Cap (Today) was E£10,200 Mil.
Total Liabilities was E£3,054 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(3409.076 - 2904.005)/5306.147
=0.0952

X2=Retained Earnings/Total Assets
=1178.2/5306.147
=0.222

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(449.037 - -530.549)/5306.147
=0.1846

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=10200.000/3053.795
=3.3401

X5=Revenue/Total Assets
=4297.175/5306.147
=0.8098

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents has a Altman Z-Score of 3.85 indicating it is in Safe Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.

Frequently Asked Questions Learn more about Altman Z-Score →
What does a Altman Z-Score of 3.85 mean?
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) has a Altman Z-Score of 3.85 as of Jul. 06, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents and its competitors. This is 26% above median its historical median of 3.06. Over the past decade, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' Altman Z-Score has ranged from 2.44 to 4.18. According to the industry distribution chart, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents ranks #428 out of 952 companies in the Drug Manufacturers industry, placing it in the top 45%.
Is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' Altman Z-Score too high?
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' current Altman Z-Score of 3.85 is 26% above median its 10-year median of 3.06. Over the past 10 years, this metric has ranged from a low of 2.44 to a high of 4.18. The Drug Manufacturers industry median Altman Z-Score is 3.29. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' value of 3.85 is 17% above this industry median. Based on the distribution chart, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents ranks #428 out of 952 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' Altman Z-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents ranks #428 out of 952 companies for Altman Z-Score. This puts Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents in the upper half of its industry. The industry median Altman Z-Score is 3.29. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' value of 3.85 is 17% above this benchmark. Historically, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' own Altman Z-Score has ranged from 2.44 to 4.18 over the past decade. While the company's 10-year median is 3.06 vs. the industry median of 3.29, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Drug Manufacturers company?
The median Altman Z-Score among Drug Manufacturers companies is 3.29, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's current Altman Z-Score of 3.85 is 17% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents and its competitors. For the Drug Manufacturers industry, the median Altman Z-Score is 3.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's current Altman Z-Score is 3.85, which is 26% above median its own 10-year median of 3.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents stock overvalued right now?
Based on GuruFocus' analysis, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) is currently considered Modestly Overvalued. The stock's GF Value™ is E£4.08, compared to a current price of E£5.10 — trading 25% above its estimated fair value. The current Altman Z-Score is 3.85, which is 26% above median its 10-year median of 3.06 and 17% above the Drug Manufacturers industry median of 3.29. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' overall GF Score™ is 84/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA), the current Altman Z-Score is 3.85 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) Overvalued in 2026?

Based on GuruFocus' analysis, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents stock appears to be overvalued. The current stock price of E£5.10 is trading 25% above its estimated GF Value™ of E£4.08. GuruFocus considers Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents to be Modestly Overvalued.

Key valuation signals for CAI:RMDA:

  • Altman Z-Score: 3.85 (26% above median its 10-year median of 3.06)
  • GF Value™: E£4.08 vs. price of E£5.10 (25% above fair value)
  • GF Score™: 84/100 with 9 warning signs
  • Industry Position: 17% above the Drug Manufacturers median (#428 of 952)

No single metric tells the full story. See the CAI:RMDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Business Description

Address No. 5 Second Industrial Zone, Sixth of October City, Giza, EGY
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents is a pharmaceutical company. The company is engaged in the Manufacturing, marketing, selling and storing of pharmaceutical reagents for human and veterinary use; manufacturing, marketing, selling and storing of diagnostic reagents necessary for individuals, laboratories and hospitals; importing pharmaceutical reagents and raw materials necessary for serving the its purposes without trading; producing pharmaceutical reagents for human and veterinary and diagnostic use for others and by others; and producing food supplements for human use for others and by others. It has two segments: production and selling of pharmaceutical products, which generates maximum revenue; and manufacturing for others (Toll manufacturing).
84GF Score

Get the complete analysis for CAI:RMDA

Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£5.10
Price
E£4.08
GF Value